Longitudinal Study of Viral Clearance and Post-Viral Outcomes

1 Background and Rationale

The critical question in post-viral fatigue syndromes is why some patients recover fully while others develop chronic conditions like ME/CFS. This study proposes a comprehensive longitudinal investigation of viral clearance dynamics to identify factors that determine recovery vs chronicity.

2 Study Design

2.1 Design Type

Prospective longitudinal cohort study with nested case-control analysis.

2.2 Sample Size

  • Total enrollment: n=500 patients with acute viral infection (SARS-CoV-2, EBV, influenza)
  • Follow-up duration: 24 months
  • Expected ME/CFS development: ~50-60 patients (10-12% based on Dubbo cohort)

2.3 Participant Groups

Primary cohort: 500 patients with confirmed acute viral infection

  • Inclusion criteria: Laboratory-confirmed acute infection, symptom onset less than 7 days, age 18-65

  • Exclusion criteria: Pre-existing ME/CFS, immunosuppression, pregnancy Comparison groups:

  • Recovered controls: Patients who return to baseline function by 6 months

  • Chronic fatigue cases: Patients meeting ME/CFS criteria at 12 months

  • Longitudinal comparators: Healthy controls (n=100) matched for age/sex

3 Assessment Schedule

Baseline (within 7 days of infection onset):

  • Viral load quantification (PCR, viral culture)

  • Comprehensive immune profiling

  • Metabolic assessment

  • Neurological and cognitive testing

  • Autonomic function testing

  • Symptom severity assessment Follow-up assessments: Weeks 2, 4, 8, 12, 24, 52

  • Repeat all baseline measures

  • Additional: Viral reservoir testing (tissue biopsies in subset)

  • Quality of life and functional capacity measures

4 Primary Hypotheses

CautionWarning

Content pending. Primary hypotheses for this study protocol have not yet been drafted.]

5 Secondary Hypotheses

CautionWarning

Content pending. Secondary hypotheses for this study protocol have not yet been drafted.]

6 Key Measures

6.1 Viral Clearance Assessment

  • Blood: Quantitative PCR for viral RNA, viral protein detection (ELISA, mass spectrometry)
  • Stool: Viral RNA and protein detection (gut reservoir assessment)
  • Tissue biopsies (subset n=100): Gut, lymph node, adipose tissue viral detection
  • Immune cells: Single-cell RNA-seq for viral transcripts in lymphocytes
  • Serum: Anti-viral antibody kinetics and avidity

6.2 Immune Profiling

  • Cellular immunity: Flow cytometry for T, B, NK, dendritic cell subsets
  • Functional assays: NK cytotoxicity, T cell proliferation, cytokine production
  • Exhaustion markers: PD-1, CTLA-4, Tim-3, LAG-3 expression
  • Cytokine profiling: 30+ cytokine panel, interferon-stimulated genes
  • Autoantibodies: GPCR autoantibodies, anti-nuclear antibodies, anti-neuronal antibodies

6.3 Metabolic Assessment

  • Mitochondrial function: PBMC respirometry (Seahorse XF), mtDNA copy number
  • Energy metabolites: Lactate, pyruvate, acylcarnitines, CoQ10
  • Hormonal assessment: Cortisol, DHEA, thyroid function
  • Autonomic testing: Heart rate variability, tilt table testing

6.4 Clinical Outcomes

  • Symptom assessment: Standardized fatigue, pain, cognitive symptom scales
  • Functional capacity: 6-minute walk test, actigraphy
  • Quality of life: SF-36, disease-specific measures
  • ME/CFS criteria: Systematic application of IOM 2015 and ICC criteria

7 Expected Outcomes and Implications

If Early Prediction Hypothesis Is Validated:

  • Enable risk stratification early in post-viral course

  • Guide targeted early intervention for high-risk patients

  • Inform understanding of ME/CFS pathophysiology

  • Provide biomarkers for clinical trials If Viral Reservoir Hypothesis Is Validated:

  • Establish viral persistence as key mechanism in ME/CFS

  • Guide development of reservoir-targeted therapies

  • Explain chronic immune activation

  • Support antiviral treatment strategies If Activation-Exhaustion Transition Is Validated:

  • Provide mechanistic explanation for disease progression

  • Identify optimal timing for different interventions

  • Explain treatment response differences between early and late disease

  • Support immune phenotype-based treatment approaches

8 Budget and Timeline

Total Budget: $3.2M over 3 years, with allocation:

  • Personnel: $1.2M (PI, Co-Is, coordinators, lab staff, statistician)

  • Laboratory assays: $1.0M (immune profiling, virology, metabolomics)

  • Participant compensation: $400K

  • Data management and analysis: $300K

  • Overhead and indirect costs: $300M Timeline:

  • Year 1: Study setup, IRB approval, begin enrollment (target n=200)

  • Year 2: Complete enrollment (total n=500), continue follow-up

  • Year 3: Complete follow-up, data analysis, manuscript preparation

9 Funding and Implementation

Target Funding Sources:

  • NIH R01 grant mechanism

  • Private foundations (Solve ME, Open Medicine Foundation)

  • Long COVID research initiatives

  • International collaborations Implementation Requirements:

  • Multi-site collaboration for adequate enrollment

  • Standardized protocols across sites

  • Centralized biorepository and data management

  • Expertise in virology, immunology, and ME/CFS

10 Ethical Considerations

Informed consent: Special procedures for acutely ill patients; clear communication of study burden and timeline Risk minimization: Invasive procedures (biopsies) limited to subset; compensation for time and travel Data safety: De-identified viral and immune data; secure storage given sensitive health information Return of results: Participants receive clinically actionable findings; research findings shared through participant portal

11 Limitations

Generalizability: Findings may not apply to non-viral triggers or pediatric ME/CFS Pathogen specificity: Focused on SARS-CoV-2, EBV, influenza; may not generalize to other triggers Observer effects: Intensive monitoring may influence health behaviors and outcomes Reservoir detection: Current methods may miss low-level or compartmentalized viral persistence

12 Expected Impact

Scientific Impact:

  • First comprehensive longitudinal study of viral clearance dynamics in post-viral fatigue

  • Identification of predictive biomarkers for ME/CFS development

  • Mechanistic understanding of transition from acute infection to chronic syndrome Clinical Impact:

  • Enable early identification of high-risk patients

  • Guide development of prevention strategies

  • Inform treatment timing and approach Patient Community Impact:

  • Provide evidence for early intervention advocacy

  • Reduce diagnostic uncertainty through biomarker development

  • Support disability claims through objective markers of dysfunction